Drug Profile
Research programme: dendritic cell vaccines - Immunomedics
Alternative Names: Dendritic cell vaccine - Immunomedics; Milatuzumab-Fab-A3B3Latest Information Update: 31 Dec 2021
Price :
$50
*
At a glance
- Originator Immunomedics
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 23 Oct 2020 Immunomedics has been acquired by Gilead Sciences
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 04 Apr 2011 Preclinical development is ongoing in USA